The Top 5 Biosimilars Articles for the Week of February 19

The Center for Biosimilars recaps the top 5 biosimilars articles for the week of February 19, 2018.


Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of February 19.

Number 5: A white paper from the Association for Accessible Medicines says that brand-name drug products are behind high prescription drug costs, and that those high costs endanger patients’ health.

Number 4: At last week’s 13th annual congress of the European Crohn's and Colitis Organisation, researchers presented findings from several studies investigating the efficacy of 2 biosimilar infliximab products.

Number 3: Investigators have released data from a 26-week open label extension of the NOR-SWITCH trial in patients with inflammatory bowel disease.

Number 2: The Patients for Biologic Safety and Access, a patient advocacy group, called on the FDA to revise its materials on biosimilars. However, some patient groups are calling PBSA’s stance into question.

Number 1: Express Scripts and Walgreens Boots are expanding their purchasing efforts to include specialty medications, such as biologics and biosimilars.

Also this week, contributor Amanda Forys, of Xcenda, explained what biosimilar manufacturers need to know about changes to the 340B Drug Pricing Program.

Finally, last week, our e-newsletter asked for your thoughts on when nonmedical substitution will become a reality in the United States.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit

Related Videos
Michael Kleinrock
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Ian Henshaw
Ian Henshaw
Ryan Haumschild, PharmD
John Gabrielson
Ryan Haumschild, PharmD, MS, MBA
Ryan Haumdschild, PharmD
Ryan Haumschild, PharmD
Related Content
© 2023 MJH Life Sciences

All rights reserved.